CRISPR Therapeutics AG (CRSP) Financial Statements (2024 and earlier)

Company Profile

Business Address BAARERSTRASSE 14
ZUG, CH-6300
State of Incorp.
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1,693,6921,739,8261,768,1031,883,1701,815,3181,895,975
Cash and cash equivalents389,477527,765444,796344,407211,885494,151
Short-term investments1,304,2151,212,0611,323,3071,538,7631,603,4331,401,824
Receivables 200,000 70,000  49
Other undisclosed current assets14,38620,76021,46924,79637,70836,679
Total current assets:1,908,0781,760,5861,859,5721,907,9661,853,0261,932,703
Noncurrent Assets
Operating lease, right-of-use asset153,993156,215159,352153,346156,921161,507
Property, plant and equipment151,945156,122159,172162,198163,634166,110
Long-term investments and receivables 1,973 4,9016,32053,13077,147
Long-term investments 1,973 4,9016,32053,13077,147
Intangible assets, net (including goodwill)163043577184
Intangible assets, net (excluding goodwill)163043577184
Restricted cash and investments11,59111,83011,79911,71711,63512,123
Other noncurrent assets1,9752,0472,1752,7604,6403,682
Total noncurrent assets:321,493326,244337,442336,398390,031420,653
TOTAL ASSETS:2,229,5712,086,8302,197,0142,244,3642,243,0572,353,356
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities83,48292,557117,426130,784105,110158,246
Taxes payable4,272
Employee-related liabilities18,906
Accounts payable38,14726,15227,58845,15327,42832,114
Accrued liabilities45,33566,40589,83885,63177,682102,954
Deferred revenue4,1053,500    
Other liabilities5,141 202020270
Other undisclosed current liabilities16,06315,17715,39115,99015,977(7,646)
Total current liabilities:108,791111,234132,837146,794121,107150,870
Noncurrent Liabilities
Long-term debt and lease obligation:      230,895
Liabilities, other than long-term debt237,977247,802248,149242,674246,47117,637
Deferred revenue14,01215,82312,32312,32312,32312,323
Other liabilities9585,3945,4845,7995,9695,314
Operating lease, liability223,007226,585230,342224,552228,179230,895
Total noncurrent liabilities:237,977247,802248,149242,674246,471248,532
Total liabilities:346,768359,036380,986389,468367,578399,402
Equity
Equity, attributable to parent1,882,8031,727,7941,816,0281,854,8961,875,4791,953,954
Common stock2,4972,4762,4742,4522,4412,433
Treasury stock, value(62)(63)(63)(63)(63)(63)
Additional paid in capital2,878,1552,821,2252,799,4202,761,0502,734,8382,709,361
Accumulated other comprehensive income (loss)1,913(6,797)(8,908)(9,388)(15,647)(22,262)
Accumulated deficit(999,700)(1,089,047)(976,895)(899,155)(846,090)(735,515)
Total equity:1,882,8031,727,7941,816,0281,854,8961,875,4791,953,954
TOTAL LIABILITIES AND EQUITY:2,229,5712,086,8302,197,0142,244,3642,243,0572,353,356

Income Statement (P&L) ($ in thousands)

3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
Revenues201,206 70,000100,000694
Gross profit:201,206 70,000100,000694
Operating expenses(131,623)(132,411)(165,223)(164,487)(131,547)(182,482)
Operating income (loss):69,583(132,411)(95,223)(64,487)(131,541)(182,388)
Nonoperating income
(Other Nonoperating income)
19,99720,67118,40612,74211,4907,264
Income (loss) from continuing operations before income taxes:89,580(111,740)(76,817)(51,745)(120,051)(175,124)
Income tax expense (benefit)(233)(412)(923)(1,320)9,476575
Income (loss) from continuing operations:89,347(112,152)(77,740)(53,065)(110,575)(174,549)
Loss before gain (loss) on sale of properties:(174,549)
Net income (loss) available to common stockholders, diluted:89,347(112,152)(77,740)(53,065)(110,575)(174,549)

Comprehensive Income ($ in thousands)

3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
Net income (loss):89,347(112,152)(77,740)(53,065)(110,575)(174,549)
Comprehensive income (loss):89,347(112,152)(77,740)(53,065)(110,575)(174,549)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent8,7102,1114806,2596,616(1,920)
Comprehensive income (loss), net of tax, attributable to parent:98,057(110,041)(77,260)(46,806)(103,959)(176,469)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: